Abstract

AAA); and generating an indicator of brain activity (Idx) of the subject when detecting the predefined pattern.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/0476 - Electroencephalography

Abstract

nm nmm, a material, a photoabsorptive film, a photoconductor, photodetector, photodiode or phototransistor, a device, the use of said plurality of metal chalcogenide nanocrystais, and a reflective or transmission filter.

IPC Classes  ?

• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 29/48 - AIIBVI compounds
• C09K 11/89 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing mercury
• H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions

Abstract

angelica dahurica, cnidium officinale, pogostemon cablin, mentha piperita, chrysanthellum americanum, camellia sinensis, zingiber officinale, citrus aurantium, saposhnikovia divaricata, eucalyptus globulus, xanthium strumariummagnolia biondiimagnolia biondii, and to the use of said composition for treating a benign disorder of short duration.

IPC Classes  ?

• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 36/232 - Angelica
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/238 - Saposhnikovia
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/534 - Mentha (mint)
• A61K 36/575 - Magnolia
• A61K 36/61 - Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 11/02 - Nasal agents, e.g. decongestants

Abstract

The present invention relates to a regenerative material in the connective tissues (such as bone, dentin or pulp) regeneration field. More precisely, the present invention relates to a connective tissue regenerative material, preferably a bone, dentin or pulp regenerative material, comprising: - a porous polymer matrix having interconnected pores; and - non-hydrated calcium silicate particles; wherein: said polymer matrix is anhydrous; said non-hydrated calcium silicate particles have a dso granulometry, preferably ranging from 0.05 iim to less than the average diameter size of the pores of the matrix; and said non-hydrated calcium silicate particles being coated on the inside walls of the pores of the matrix. The present invention also relates to method for preparing said connective tissue regenerative material. The present invention also concerns uses of said regenerative materials, such as for example in the dental field; especially, for providing regenerative materials with improved biomechanical and osteoinductive properties (i.e. good migration, adhesion and proliferation of cells; enhanced mechanical properties; and optimal and controlled biodegradability).

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix

Abstract

The invention relates to the extraction of organic compounds from mixtures of said compounds with water, using a nanoporous carbon membrane. The invention can be used in any field where it is desired to separate an organic compound of interest from water, such as the drying of alcohols or alkanes.

IPC Classes  ?

• C07C 29/76 - SeparationPurificationStabilisationUse of additives by physical treatment
• C07C 31/08 - Ethanol
• C07C 31/12 - Monohydroxylic acyclic alcohols containing four carbon atoms
• C07B 63/00 - PurificationSeparation specially adapted for the purpose of recovering organic compoundsStabilisationUse of additives
• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C07C 7/144 - Purification, separation or stabilisation of hydrocarbonsUse of additives using membranes, e.g. selective permeation

Abstract

The present invention relates to an in-ear stimulation system comprising a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject; wherein each of the first device and the second device comprises: − at least one in-ear active electrode (11,21) configured to receive a bio-signal and at least one in-ear reference electrode (12, 22) configured to receive a bio-signal; − at least one stimulation device (13, 23) configured for emitting at least one electrical or sensory stimulus; and − an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

The present invention relates to an agonist of the receptor of 1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid, preferably an agonist of two- pore channel 1 (TPC1) and/or two-pore channel 2 (TPC2), for the treatment and/or prevention of neurodegenerative disorders.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/10 - AntiepilepticsAnticonvulsants for petit-mal

Abstract

The present invention relates to a method for the differentiation of pluripotent stem cells into cardiomyocytes, comprising a step of activating at least one cardiac tissue-specific transcription factor.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention relates to an in vitro method for the prognostic of a subject affected by a demyelinating disease comprising detecting and quantifying the level of at least one of CCL19, IL-15, ENA78 and/or TRAIL in a biological fluid from the subject. The invention also relates to the treatment of a subject affected by a demyelinating disease comprising the use of at least one modulator of CCL19, IL-15, ENA78 and/or TRAIL.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a X-ray fluorescence molecular probe of formula I or a salt thereof, wherein X, Het 1, R1, Y1, Y2, L and R2 are as defined in the claims. The invention also relates to the use of the probes of the invention for X-ray fluorescence imaging, including in the context of multimodal imaging. The probes of the invention are useful in biological applications of X-ray fluorescence imaging, especially for imaging intracellular organelles and to label biomolecules. The probes of the invention may be functionalized or functionalizable.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic Table

Abstract

The present invention relates to a cell culture device comprising a mesh comprising or made of a biocompatible polymer; and a top grid comprising or made of a biocompatible polymer, laying over the said mesh; wherein the mesh is a monolayer of cross-linked nanofibers and has a specific surface ranging from 20% to 40%; the top grid comprises a single grid and an array of openings separated by partitions having a width; each opening of the top grid has the same geometric configuration; and the top grid comprises a border surrounding the openings, the said border having a width at least two times greater than the width of the said partitions. The present invention also relates to a method for manufacturing said cell culture device, a method of cell growth or differentiation and a cell culture system.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• C12M 1/09 - Flotation apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The invention relates to the use of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X- are as defined in the claims, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl, for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.

IPC Classes  ?

• A61B 5/0476 - Electroencephalography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes

Abstract

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

IPC Classes  ?

• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• C07D 239/00 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention relates to a composition comprising classic bis-ureas and bis-ureas functionalised by macromolecular chains, said bis-ureas including complementary spacers of the aryl type, the mixture of said bis-ureas in a solvent leading to a stable physical gel. The invention also relates to a method for producing said composition and to the use of said composition as an organogelator, alone or in a cosmetic preparation, an ink, a fuel or a lubricant, especially of a motor vehicle.

IPC Classes  ?

• C08K 5/21 - UreaDerivatives thereof, e.g. biuret
• C10M 133/20 - UreasSemicarbazidesAllophanates
• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups

Abstract

A nine-hole pegboard test and a click test on the dominant hand are combined to obtain a score for the diagnosis of cerebellar impairment.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

The present invention relates to a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labelling particles, e.g. proteins, or surfaces, which is capable of binding reversibly a fluorogenic chromophore of formula (I), and which is capable of enhancing the brightness of the said fluorogenic chromophore upon complexation thereto; and of inducing the spectral shift of the said fluorogenic chromophore through the ionization of an auxochromic group thereof.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07D 277/26 - Radicals substituted by sulfur atoms

Abstract

The present invention relates to novel fluoroquinolones, pharmaceutical compositions or medicament containing them and use thereof to treat bacterial infection.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a reconstituted high density lipoprotein composition comprising negatively charged phospholipids to enhance cholesterol clearance, reduce inflammation and other anti-atherosclerotic actions.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a composition comprising a depolarizing agent acting on a receptor expressed by the dopamine neurons of the substantia nigra, and a modulator of the nicotinic cholinergic pathway, wherein said receptor expressed by the dopamine neurons of the substantia nigra is an orexin receptor, a purinergic receptor or a neurokinin receptor; and to the use thereof for proving neuroprotection to a subject or for treating a disease, disorder or condition related to the dysfunction of the dopamine neurons of the substantia nigra in a subject.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a method for diagnosing an epileptic disease, disorder or condition in a subject, or determining a predisposition of a subject to an epileptic disease, disorder or condition or determining an increased risk of a subject of developing an epileptic disease, disorder or condition, wherein said method comprises determining the status of the DEPDC5 gene of the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, or determining a predisposition of a subject to a neurodegenerative disease or determining an increased risk of a subject of developing a neurodegenerative disease, wherein said method comprises determining the protein level of C90RF72 in a body fluid of the subject, and comparing said protein level to a reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids